HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

Breast Cancer Research and Treatment
Yuanyuan LiuX Zeng

Abstract

Human epidermal growth factor receptor 2 (HER2) status is both an independent prognostic factor and a predictive factor for the efficacy of targeted therapy for breast cancer, so it is critical to accurately detect HER2 protein expression and/or gene amplification. According to the recommendations of the 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines for HER2 breast cancer testing, an additional test should be pursued on a different block from the same tumor as one of the options for patients with immunohistochemistry (IHC) 2+ and a HER2/CEP17 ratio of < 2.0 with an average HER2 signals per tumor cell of ≥ 4.0 and < 6.0 by reflex test using dual-probe fluorescence in situ hybridization (FISH) (double-equivocal HER2). Our aim in this study is to explore the consistency of HER2 status between the two blocks. We retrospectively analyzed 5685 primary invasive breast cancers between April 2015 and January 2019 from Peking Union Medical College Hospital. For cases with double-equivocal HER2 revealed in initial blocks, HER2 gene status was evaluated by FISH in a different block from the same tumor. The FISH score was interpreted according to the 2013 ASCO/CAP guidelines for HER2 t...Continue Reading

References

Jan 1, 1990·Cancer Investigation·D J Slamon
Jul 6, 2004·Genes, Chromosomes & Cancer·Camilo AdemRobert B Jenkins
Feb 27, 2007·The Breast Journal·Wedad HannaHarriette J Kahn
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Oct 7, 2015·Current Pharmacology Reports·Joseph Wahler, Nanjoo Suh
Dec 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N NiikuraY Tokuda
Dec 17, 2016·International Journal of Molecular Sciences·Quanxia LvGe Zhang
Jan 2, 2018·International Journal of Surgery Case Reports·Irean Garcia HernandezGabriela Sofia Gomez Macias
May 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffMitchell Dowsett

❮ Previous
Next ❯

Citations

Apr 9, 2020·Cancer Immunology, Immunotherapy : CII·Liju ZongYang Xiang
Aug 23, 2020·Pathology, Research and Practice·Raquel Machado-NevesAntónio Polónia
May 6, 2021·International Journal of Molecular Sciences·Vincenza Ylenia CusenzaRaffaele Frazzi

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
surgical resection

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.